

## COMPOSITION "J"

## Insufflation


One hundred grams of an active ingredient in bulk form is finely divided by means of an air micronizer.

The foregoing composition is useful for treating antineoplastic disease, by the inhalation of 300 mg one to four times a day.

From the foregoing, it becomes readily apparent that a new and useful antineoplastic factor and new and useful antineoplastic preparations have been herein described and illustrated which fulfill all of the aforesaid objectives in a remarkably unexpected fashion. It is of course understood that such modifications, alterations and adaptations as will readily occur to the artisan confronted with this disclosure are intended within the spirit of the present invention.

Claims:

1. A pharmaceutical preparation for treating neoplastic disease comprising a pharmaceutically acceptable carrier and a tumor-inhibiting amount of a yujungamycin.
2. A preparation according to claim 1 in which said yujungamycins have the structural formula:




wherein: R = H, CONH<sub>2</sub>, COCH<sub>3</sub>.

3. A pharmaceutical preparation according to claim 2 in which said yujungamycins has a configuration of S(-) or R(+).

4. A pharmaceutical preparation according to claim 1 in which said yujungamycin is selected from the group consisting of 3-acetamido-6-aziridinyl-2,3-dihydro-7-methyl-1*H*-pyrrolo[1,2- $\alpha$ ] benzimidazole-5,8-dione; 3-amino-6-aziridinyl-2,3-dihydro-7-methyl-1*H*-pyrrolo[1,2- $\alpha$ ] benzimidazole-5,8-dione; and 3-carbamido-6-aziridinyl-2,3-dihydro-7-methyl-1*H*-pyrrolo[1,2- $\alpha$ ] benzimidazole-5,8-dione.


- 10 5. A pharmaceutical preparation for treating a neoplastic disease selected from the group consisting of central nervous system cancer, colon cancer, ovarian cancer, and lung cancer comprising a pharmaceutically acceptable carrier and a tumor-inhibiting amount of a compound selected from the group consisting of yujungamycins having the structural formula:



wherein R is selected from the group consisting of H, COCH<sub>3</sub> and CONH<sub>2</sub>.

6. A pharmaceutical preparation according to claim 5 in which said yujungamycins has a configuration of S(-) or R(+).
- 20 7. A pharmaceutical preparation according to claim 5 in which said yujungamycin is selected from the group consisting of 3-acetamido-6-aziridinyl-2,3-dihydro-7-methyl-1*H*-pyrrolo[1,2- $\alpha$ ] benzimidazole-5,8-dione; 3-amino-6-aziridinyl-2,3-dihydro-7-methyl-1*H*-pyrrolo[1,2- $\alpha$ ] benzimidazole-5,8-dione; and 3-carbamido-6-aziridinyl-2,3-dihydro-7-methyl-1*H*-pyrrolo[1,2- $\alpha$ ] benzimidazole-5,8-dione.

8. A method of treating a host afflicted with a neoplastic disease selected from the group consisting of central nervous system cancer, colon cancer, ovarian cancer, and lung cancer comprising administering to said host an effective amount of a compound selected from the group consisting of yujungamycins having the structural formula



wherein: R is H, CONH<sub>2</sub> or COCH<sub>3</sub>.

9. A pharmaceutical preparation according to claim 8 in which said yujungamycin has a configuration of S(-) or R(+).
10. A pharmaceutical preparation according to claim 8 in which said yujungamycin is selected from the group consisting of 3-acetamido-6-aziridinyl-2,3-dihydro-7-methyl-1H-pyrrolo[1,2-α] benzimidazole-5,8-dione; 3-amino-6-aziridinyl-2,3-dihydro-7-methyl-1H-pyrrolo[1,2-α] benzimidazole-5,8-dione; and 3-carbamido-6-aziridinyl-2,3-dihydro-7-methyl-1H-pyrrolo[1,2-α] benzimidazole-5,8-dione.